These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31585935)

  • 21. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.
    Tsuchikawa T; Hirano S; Tanaka E; Matsumoto J; Kato K; Nakamura T; Ebihara Y; Shichinohe T
    Cancer Sci; 2013 May; 104(5):531-5. PubMed ID: 23363422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
    Norgard RJ; Budhani P; O'Brien SA; Xia Y; Egan JN; Flynn B; Tagore JR; Seco J; Peet GW; Mikucka A; Wasti R; Chan LC; Hinkel M; Martinez-Morilla S; Pignatelli J; Trapani F; Corse E; Feng D; Kostyrko K; Hofmann MH; Liu K; Kashyap AS
    Cancer Res Commun; 2024 Jun; 4(6):1548-1560. PubMed ID: 38727236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
    Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
    Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
    Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ
    Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
    Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
    BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.
    Grage-Griebenow E; Jerg E; Gorys A; Wicklein D; Wesch D; Freitag-Wolf S; Goebel L; Vogel I; Becker T; Ebsen M; Röcken C; Altevogt P; Schumacher U; Schäfer H; Sebens S
    Mol Oncol; 2014 Jul; 8(5):982-97. PubMed ID: 24746181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
    Oweida AJ; Mueller AC; Piper M; Milner D; Van Court B; Bhatia S; Phan A; Bickett T; Jordan K; Proia T; Schulick R; Messersmith WA; Del Chiaro M; Clambey E; Gough MJ; Williams J; Hansen K; Goodman K; Karam SD
    Cancer Immunol Immunother; 2021 Apr; 70(4):989-1000. PubMed ID: 33097963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hirsutella sinensis Inhibits Lewis Lung Cancer via Tumor Microenvironment Effector T Cells in Mice.
    Fu H; Jin L; Shao X; Li Y; Chen F; Shou Z; Tang X; Ji B; Shou Q
    Am J Chin Med; 2018; 46(4):911-922. PubMed ID: 29754506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Hiraoka N; Onozato K; Kosuge T; Hirohashi S
    Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-derived suppressor cells and their role in pancreatic cancer.
    Pergamo M; Miller G
    Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Immune Microenvironment in Pancreatic Cancer.
    Huber M; Brehm CU; Gress TM; Buchholz M; Alashkar Alhamwe B; von Strandmann EP; Slater EP; Bartsch JW; Bauer C; Lauth M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33022971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.